AKRO
Akero Therapeutics Inc

2,288
Loading...
Loading...
News
all
press releases
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Zacks·11h ago
News Placeholder
More News
News Placeholder
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Zacks·12h ago
News Placeholder
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Zacks·1d ago
News Placeholder
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Zacks·4d ago
News Placeholder
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.
Zacks·8d ago
News Placeholder
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.1% in Akero Therapeutics (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·9d ago
News Placeholder
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Zacks·15d ago
News Placeholder
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Zacks·22d ago
News Placeholder
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Zacks·24d ago
News Placeholder
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Zacks·1mo ago

Latest AKRO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.